Abstract:The biosafety of Lactobacillus plantarum SLlac-23 was comprehensively evaluated by analyzing its tolerance in simulated gastric and intestinal fluid environments in vitro，combined with acute and chronic oral toxicity tests，antibiotic susceptibility tests，and hemolytic activity detection using the blood agar plate method.Additionally，the impact of long-term intake on host health was verified by measuring hepatic and renal function indicators in a mouse model，including serum alanine aminotransferase（ALT），aspartate aminotransferase（AST），creatinine（Cr），and blood urea nitrogen（BUN）.The results showed that the survival rate of SLlac-23 exceeded 88% in both simulated gastric and intestinal fluids，indicating good gastrointestinal tolerance.The strain exhibited no hemolytic activity.No mortality or abnormal behavior was observed in oral toxicity tests.Compared with the control group，there were no significant differences in body weight，organ indices，or hepatic and renal function indicators（P>0.05）.Based on these findings，Lactobacillus plantarum SLlac-23 with the uric acid-lowering effect exhibited excellent safety and showed potential for clinical development as a probiotic preparation for reducing uric acid levels.